RIPE-KG · Version 1.1.0 · Resource
ripekg:work/10.1200%2Fjco.24.00938
https://w3id.org/ripe/ripe-kg/work/10.1200%2Fjco.24.00938
| Subject | Predicate | Object |
|---|---|---|
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial |
http://purl.org/spar/cito/cites |
ripekg:work/10.1200%2Fjco.24.00938Metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: the phase III MECCA trial |
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies |
http://purl.org/spar/cito/cites |
ripekg:work/10.1200%2Fjco.24.00938Metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: the phase III MECCA trial |
ripekg:work/10.1200%2Fjco.24.00938Metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: the phase III MECCA trial |
prism:doi |
10.1200/jco.24.00938 |
ripekg:work/10.1200%2Fjco.24.00938Metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: the phase III MECCA trial |
dcterms:title |
Metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: the phase III MECCA trial |
ripekg:work/10.1200%2Fjco.24.00938Metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: the phase III MECCA trial |
rdf:type |
node1 |
ripekg:work/10.1200%2Fjco.24.00938Metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: the phase III MECCA trial |
rdf:type |
http://purl.org/spar/fabio/Work |
ripekg:work/10.1200%2Fjco.24.00938Metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: the phase III MECCA trial |
rdf:type |
rdfs:Resource |
ripekg:work/10.1200%2Fjco.24.00938Metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: the phase III MECCA trial |
rdf:type |
owl:Thing |
ripekg:work/10.1200%2Fjco.24.00938Metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: the phase III MECCA trial |
rdf:type |
prov:Entity |
ripekg:work/10.1200%2Fjco.24.00938Metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: the phase III MECCA trial |
rdf:type |
ripe:WorkWork |
ripekg:work/10.1200%2Fjco.24.00938Metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: the phase III MECCA trial |
owl:sameAs |
https://semopenalex.org/work/W4406010713 |